AGEN earnings analysis
What we found in AGEN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Agenus delivered materially improved Q2 results, with revenue up 34.3% year over year to $34.518 million, a $11.293 million operating profit and diluted EPS of $(0.01) versus $(1.00) in Q2 2025. The improvement was driven largely by $28.146 million of non-cash royalty revenue, cost reductions and $6.372 million of early-access BOT/BAL revenue, while operating cash use increased to $67.149 million for the first half. Liquidity was strengthened by the Zydus transaction and a subsequent $85.0 million private placement, but substantial doubt about going-concern status, near-term debt maturities and the need for additional capital remain significant constraints.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 34% year over year
- Q2 2026 revenue increased 34.3% year over year to $34.518 million from $25.691 million, driven by $28.146 million of non-cash royalty revenue and $6.372 million of pre-commercial BOT/BAL revenue. Revenue was broadly stable sequentially versus approximately $34 million in Q1 2026.
- Operating income turned positive
- Gross margin was effectively 100.0% in Q2 2026 because cost of revenue was $0, compared with 99.0% in Q2 2025. Operating income was $11.293 million versus an operating loss of $16.711 million a year earlier, a $27. a million improvement, although the quarter benefited from the high-margin royalty revenue stream.
- EPS loss narrowed materially
- Diluted loss per share improved to $(0.01) in Q2 2026 from $(1.00) in Q2 2025, while Q1 2026 diluted EPS was $1.02. Net loss attributable to common stockholders was $0.604 million versus $28.009 million in Q2 2025.
- Early-access revenue expanded
- Pre-commercial BOT/BAL revenue reached $6.372 million in Q2 2026 and $10.963 million for the first six months, reflecting France’s AAC framework and paid named-patient programs. Management expects to collect outstanding early-access receivables during Q3 2026.
- Liquidity improved after financings
- Cash and cash equivalents increased to $18.738 million at June 30, 2026 from $2.998 million at December 31, 2025, excluding $7.616 million held in Zydus escrow. The Zydus transaction generated $63.917 million of net investing proceeds, while the July private placement provided approximately $85.0 million of upfront gross proceeds after quarter-end.
- ROBBIN program provides strategic focus
- Management plans to prioritize the ROBBIN Phase 3 trial in neoadjuvant MSS colon cancer. The trial is expected to enroll 850 patients, with the first patient dosed in Q1 2027 and interim pathologic response data anticipated in the second half of 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating cash burn remains elevated
- The company used $67.149 million of cash in operating activities during the first six months of 2026, up from $45.840 million in the prior-year period. Working-capital outflows included a $23.981 million reduction in accounts payable and a $12.894 million increase in accounts receivable.
- Going-concern uncertainty persists
- Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after the filing date. The company had an accumulated deficit of $2.1 billion as of June 30, 2026 and says additional capital is required to fund BOT/BAL registration, commercialization and profitability.
- Near-term debt and royalty obligations
- Principal debt outstanding was $30.4 million at June 30, 2026, including $24.75 million due in November 2026 and $5.1 million due in January 2027. The company also recorded $249.465 million of net liabilities related to sales of future royalties and milestones.
- Substantial financing dilution risk
- The July private placement increased potential dilution: the company issued or agreed to issue 23,035,227 common shares and warrants for up to 54,941,491 additional shares. The warrants could provide up to $255.0 million of gross proceeds, but exercise is at holders’ discretion and is not assured.
- BATTMAN program was terminated
- Agenus discontinued its planned future financial contribution to the BATTMAN Phase 3 study, after which CCTG formally terminated the trial. The company states the decision reflected financing and development priorities rather than enrollment, efficacy or safety findings.
- Litigation remains unresolved
- The securities class-action dismissal is being appealed in the First Circuit, while four derivative actions remain consolidated and stayed. The company cannot estimate a loss range for an adverse outcome in either the appeal or derivative actions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
- Gross margin
- 100.0%
- Operating margin
- 32.7%
- Segment
- Single reportable segment: immunotherapy discovery, development and manufacturing; Q2 2026 revenue $34.518 million versus $25.691 million in Q2 2025.
What they said about what is next.
No explicit EPS or revenue guidance was provided. Management expects existing cash and net private-placement proceeds to fund operations and capital expenditures into Q3 2027, assuming no warrant exercise; if all warrants are exercised for cash, funding could extend through year-end 2031. Management also states that additional capital will be required to advance BOT/BAL registration and commercialization and reach profitability.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Agenus reported Q1 2026 revenue of $33.7 million and an EPS of $1.95, surpassing estimates of $129.5 million and $1.83, respectively. The company achieved growth in pre-commercial product revenue and recognized gains…
- 10-K · March 16, 2026
- Agenus is intentionally focused on advancing its lead BOT/BAL immuno‑oncology program after a December 2024 strategic realignment, began recognizing paid early‑access revenue in H2 2025, and closed a $91.0 million…
- 10-Q · November 10, 2025
- Agenus reported quarterly revenue of $30.235 million and diluted EPS of $1.94 for the three months ended September 30, 2025, driven predominantly by non‑cash royalty revenue and a $100.9 million gain on the…
- 10-K · March 17, 2025
- Agenus continues to focus strategically on developing innovative immuno-oncology therapies, particularly the BOT/BAL combination for colorectal cancer. Despite revenue challenges in 2024, the company's restructuring…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AGEN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever